scholarly article | Q13442814 |
P356 | DOI | 10.3390/PH11010012 |
P8608 | Fatcat ID | release_ic2l3c5zgrd6vdtzynfsr7pjcq |
P932 | PMC publication ID | 5874708 |
P698 | PubMed publication ID | 29382156 |
P50 | author | Marcia Regina Cominetti | Q42842705 |
Patricia R Manzine | Q57057789 | ||
Rafaela Peron | Q92674090 | ||
Antoni Camins | Q38639318 | ||
P2093 | author name string | Izabela Pereira Vatanabe | |
P2860 | cites work | APP binds DR6 to trigger axon pruning and neuron death via distinct caspases | Q22251088 |
The TspanC8 subgroup of tetraspanins interacts with A disintegrin and metalloprotease 10 (ADAM10) and regulates its maturation and cell surface expression | Q24300299 | ||
TspanC8 tetraspanins regulate ADAM10/Kuzbanian trafficking and promote Notch activation in flies and mammals | Q24301578 | ||
SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. | Q24601406 | ||
Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy | Q24631354 | ||
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib | Q24655048 | ||
In vivo fate analysis reveals the multipotent and self-renewal capacities of Sox2+ neural stem cells in the adult hippocampus | Q24683755 | ||
Sirtuin functions and modulation: from chemistry to the clinic | Q26745884 | ||
A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditions | Q26781560 | ||
The functions of animal microRNAs | Q27860621 | ||
The widespread regulation of microRNA biogenesis, function and decay | Q28131796 | ||
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy | Q28282855 | ||
Neuroprotective Sirtuin ratio reversed by ApoE4 | Q28300666 | ||
The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity | Q40360129 | ||
Genomic structure and functional characterization of the human ADAM10 promoter | Q40406214 | ||
Melatonin attenuates amyloid beta25-35-induced apoptosis in mouse microglial BV2 cells | Q40430504 | ||
Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. | Q40457061 | ||
Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. | Q40520119 | ||
Expression of the anti-amyloidogenic secretase ADAM10 is suppressed by its 5'-untranslated region | Q40601806 | ||
Intrahippocampal Administration of Ibotenic Acid Induced Cholinergic Dysfunction via NR2A/NR2B Expression: Implications of Resveratrol against Alzheimer Disease Pathophysiology | Q40622685 | ||
Regulation of the alpha-secretase ADAM10 by its prodomain and proprotein convertases. | Q40789097 | ||
G-quadruplexes: the beginning and end of UTRs | Q41847081 | ||
ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase | Q42059040 | ||
Metallothionein-III antagonizes the neurotoxic and neurotrophic effects of amyloid beta peptides | Q43636525 | ||
Effects of Zn(2+), Ca(2+), and Mg(2+) on the structure of Zn(7)metallothionein-3: evidence for an additional zinc binding site | Q43665222 | ||
Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide | Q43683499 | ||
Anti-amyloid beta activity of metallothionein-III is different from its neuronal growth inhibitory activity: structure-activity studies | Q44265128 | ||
BACE1 levels correlate with phospho-tau levels in human cerebrospinal fluid | Q44408042 | ||
Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease | Q44444828 | ||
Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels | Q44530237 | ||
Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease | Q45009958 | ||
Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain | Q45014651 | ||
Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. | Q45963204 | ||
Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials | Q46390270 | ||
ADAM and Eph: how Ephrin-signaling cells become detached | Q46765672 | ||
Diversity of microRNAs in human and chimpanzee brain | Q47179611 | ||
Structural Basis for Regulated Proteolysis by the α-Secretase ADAM10. | Q47311068 | ||
Sox2 functionally interacts with βAPP, the βAPP intracellular domain and ADAM10 at a transcriptional level in human cells | Q47617536 | ||
microRNA 221 Targets ADAM10 mRNA and is Downregulated in Alzheimer's Disease. | Q47646473 | ||
ADAM10 as a therapeutic target for brain diseases: from developmental disorders to Alzheimer's disease | Q47728000 | ||
Regulation of ADAM10 by miR-140-5p and potential relevance for Alzheimer's disease | Q47908768 | ||
Serotoninergic antidepressants positively affect platelet ADAM10 expression in patients with Alzheimer's disease | Q48070770 | ||
Enhanced neurotrophic activity in Alzheimer's disease cortex is not associated with down-regulation of metallothionein-III (GIF). | Q48103518 | ||
Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment | Q48147007 | ||
Metallothionein-I and -III expression in animal models of Alzheimer disease | Q48402258 | ||
Changes in melatonin secretion with age and pubescence | Q48409455 | ||
Generation of an apoptotic intracellular peptide by gamma-secretase cleavage of Alzheimer's amyloid beta protein precursor. | Q48492125 | ||
Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. | Q48552163 | ||
Regulation of metallothionein-III (GIF) mRNA in the brain of patients with Alzheimer disease is not impaired | Q48560961 | ||
Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease | Q48570738 | ||
Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking | Q48770281 | ||
Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease | Q48795523 | ||
Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease | Q48895286 | ||
Metallothionein III is reduced in Alzheimer's disease | Q48955424 | ||
Dysregulated ADAM10-Mediated Processing of APP during a Critical Time Window Leads to Synaptic Deficits in Fragile X Syndrome | Q50259561 | ||
Maintenance of Cognitive Performance and Mood for Individuals with Alzheimer's Disease Following Consumption of a Nutraceutical Formulation: A One-Year, Open-Label Study. | Q50663391 | ||
Discovery of Small Molecules for Up-Regulating the Translation of Antiamyloidogenic Secretase, a Disintegrin and Metalloproteinase 10 (ADAM10), by Binding to the G-Quadruplex-Forming Sequence in the 5' Untranslated Region (UTR) of Its mRNA. | Q50994587 | ||
Protein Expression of BACE1 is Downregulated by Donepezil in Alzheimer's Disease Platelets. | Q51061879 | ||
Resveratrol Intervenes Cholesterol- and Isoprenoid-Mediated Amyloidogenic Processing of AβPP in Familial Alzheimer's Disease. | Q51212850 | ||
The Roles of Endoplasmic Reticulum Stress in the Pathophysiological Development of Cartilage and Chondrocytes. | Q51361479 | ||
Melatonin stimulates the nonamyloidogenic processing of βAPP through the positive transcriptional regulation of ADAM10 and ADAM17. | Q52994249 | ||
The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma. | Q53222639 | ||
Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin. | Q53358084 | ||
Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. | Q53370360 | ||
SAP97-mediated local trafficking is altered in Alzheimer disease patients' hippocampus. | Q53417845 | ||
Alterations in Nocturnal Serum Melatonin Levels In Humans With Growth and Aging* | Q68291626 | ||
A note on the relevance of [6]-Gingerol for the prevention and/or treatment of Alzheimer's disease | Q85472485 | ||
Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study | Q28366850 | ||
Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain | Q28507690 | ||
Regulation of hepatic lipogenesis by the transcription factor XBP1 | Q28507784 | ||
Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity | Q28511294 | ||
Activation of SIRT1 by curcumin blocks the neurotoxicity of amyloid-β25-35 in rat cortical neurons | Q28580285 | ||
RDH10 is essential for synthesis of embryonic retinoic acid and is required for limb, craniofacial, and organ development | Q28587012 | ||
Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer's disease | Q29048183 | ||
Therapeutic potential of resveratrol: the in vivo evidence | Q29547413 | ||
The RXR heterodimers and orphan receptors | Q29547867 | ||
APP processing and synaptic function | Q29615873 | ||
PDZ domain proteins of synapses | Q29616399 | ||
Sex and gender differences in the treatment of Alzheimer's disease: A systematic review of randomized controlled trials | Q30240257 | ||
Protective effect of melatonin on beta-amyloid-induced apoptosis in rat astroglioma C6 cells and its mechanism | Q33208711 | ||
The role of Wnt signaling in the development of Alzheimer's disease: a potential therapeutic target? | Q33634629 | ||
PAX2 regulates ADAM10 expression and mediates anchorage-independent cell growth of melanoma cells | Q34005367 | ||
Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression | Q34111025 | ||
Sox2(+) adult stem and progenitor cells are important for tissue regeneration and survival of mice | Q34222321 | ||
Computational identification and experimental validation of microRNAs binding to the Alzheimer-related gene ADAM10. | Q34272420 | ||
Increased BMP6 levels in the brains of Alzheimer's disease patients and APP transgenic mice are accompanied by impaired neurogenesis | Q34299878 | ||
Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. | Q34414355 | ||
Pax genes and organogenesis. | Q34439185 | ||
Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson's disease and Alzheimer's disease | Q34543231 | ||
SAP97-mediated ADAM10 trafficking from Golgi outposts depends on PKC phosphorylation | Q34662305 | ||
Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. | Q34737994 | ||
Inhibition of Alzheimer beta-fibrillogenesis by melatonin | Q34746395 | ||
Evidence for defective retinoid transport and function in late onset Alzheimer's disease | Q34809021 | ||
Cholesterol and pathological processes in Alzheimer's disease | Q34976268 | ||
Statins and their role in vascular protection | Q35148303 | ||
Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans | Q35202803 | ||
Soluble amyloid precursor protein: a novel proliferation factor of adult progenitor cells of ectodermal and mesodermal origin | Q35558510 | ||
The Functional Maturation of A Disintegrin and Metalloproteinase (ADAM) 9, 10, and 17 Requires Processing at a Newly Identified Proprotein Convertase (PC) Cleavage Site | Q35583121 | ||
PAX Genes in Cancer; Friends or Foes? | Q35714437 | ||
Activation of peroxisome proliferator-activated receptor α stimulates ADAM10-mediated proteolysis of APP | Q35845926 | ||
Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice | Q35996371 | ||
Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer's disease | Q36137410 | ||
Evidence that the amyloid-β protein precursor intracellular domain, AICD, derives from β-secretase-generated C-terminal fragment | Q39382095 | ||
Regulation of the trafficking and the function of the metalloprotease ADAM10 by tetraspanins. | Q39422025 | ||
[6]-Gingerol attenuates β-amyloid-induced oxidative cell death via fortifying cellular antioxidant defense system | Q39577488 | ||
Activation of α-secretase by curcumin-aminoacid conjugates | Q39586120 | ||
Rescue of Hypovitaminosis A Induces Non-Amyloidogenic Amyloid Precursor Protein (APP) Processing. | Q39661608 | ||
Statins and the squalene synthase inhibitor zaragozic acid stimulate the non-amyloidogenic pathway of amyloid-beta protein precursor processing by suppression of cholesterol synthesis | Q39711618 | ||
Loss of HRD1-mediated protein degradation causes amyloid precursor protein accumulation and amyloid-beta generation | Q39726471 | ||
Regulation of secretases by all-trans-retinoic acid | Q39846093 | ||
Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin | Q39895248 | ||
Tetraspanins regulate ADAM10-mediated cleavage of TNF-alpha and epidermal growth factor | Q39921892 | ||
Modulatory effect of acetyl-L-carnitine on amyloid precursor protein metabolism in hippocampal neurons. | Q39938504 | ||
Translational repression of the disintegrin and metalloprotease ADAM10 by a stable G-quadruplex secondary structure in its 5'-untranslated region | Q40041919 | ||
Statins reduce amyloid-beta production through inhibition of protein isoprenylation | Q40103529 | ||
Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease. | Q40269778 | ||
Shedding light on ADAM metalloproteinases | Q36159565 | ||
A PANorama of PAX genes in cancer and development | Q36362388 | ||
Re-assessing the relationship between cholesterol, statins and Alzheimer's disease | Q36546507 | ||
Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease | Q36604044 | ||
Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis | Q37151717 | ||
Regulation of cyclic AMP response element binding and hippocampal plasticity-related genes by peroxisome proliferator-activated receptor α. | Q37244012 | ||
All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease | Q37630540 | ||
A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1. | Q37820658 | ||
A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2. | Q37824843 | ||
α-Secretase in Alzheimer's disease and beyond: mechanistic, regulation and function in the shedding of membrane proteins | Q37878498 | ||
Alpha-secretase cleavage of the amyloid precursor protein: proteolysis regulated by signaling pathways and protein trafficking | Q37878501 | ||
Melatonin as a natural ally against oxidative stress: a physicochemical examination. | Q37900675 | ||
Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin | Q37959556 | ||
MicroRNA networks surrounding APP and amyloid-β metabolism--implications for Alzheimer's disease | Q37961383 | ||
MicroRNAs in Alzheimer's disease | Q37979612 | ||
On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. | Q38045452 | ||
Alzheimer's disease, cholesterol, and statins: the junctions of important metabolic pathways | Q38071004 | ||
Tetraspanin proteins promote multiple cancer stages | Q38186043 | ||
[6]-gingerol as a cancer chemopreventive agent: a review of its activity on different steps of the metastatic process | Q38189458 | ||
Tetraspanins at a glance. | Q38240344 | ||
The transcription factor X-box binding protein-1 in neurodegenerative diseases | Q38248723 | ||
Strategy to reduce free radical species in Alzheimer's disease: an update of selected antioxidants. | Q38253060 | ||
Identification of a Pax paired domain recognition sequence and evidence for DNA-dependent conformational changes | Q38310017 | ||
The Roles of the Stem Cell-Controlling Sox2 Transcription Factor: from Neuroectoderm Development to Alzheimer's Disease? | Q38359533 | ||
The alpha secretase ADAM10: A metalloprotease with multiple functions in the brain | Q38622031 | ||
Regulation of the α-secretase ADAM10 at transcriptional, translational and post-translational levels | Q38802753 | ||
Apolipoprotein E-mediated Modulation of ADAM10 in Alzheimer's Disease | Q38977248 | ||
Cilostazol suppresses β-amyloid production by activating a disintegrin and metalloproteinase 10 via the upregulation of SIRT1-coupled retinoic acid receptor-β. | Q38987753 | ||
Metallothionein-III increases ADAM10 activity in association with furin, PC7, and PKCα during non-amyloidogenic processing. | Q38991860 | ||
Unfolded protein response signaling by transcription factor XBP-1 regulates ADAM10 and is affected in Alzheimer's disease. | Q39069488 | ||
High bioavailability curcumin: an anti-inflammatory and neurosupportive bioactive nutrient for neurodegenerative diseases characterized by chronic neuroinflammation | Q39138022 | ||
Mechanisms of Melatonin in Alleviating Alzheimer's Disease | Q39178920 | ||
Regulation of Alpha-Secretase ADAM10 In vitro and In vivo: Genetic, Epigenetic, and Protein-Based Mechanisms | Q39214249 | ||
Scissor sisters: regulation of ADAM10 by the TspanC8 tetraspanins. | Q39376860 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P921 | main subject | Alzheimer's disease | Q11081 |
P577 | publication date | 2018-01-29 | |
P1433 | published in | Pharmaceuticals | Q15750667 |
P1476 | title | Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment. | |
P478 | volume | 11 |
Q64084359 | Enhanced Expression of Secreted α-Klotho in the Hippocampus Alters Nesting Behavior and Memory Formation in Mice |
Q89879825 | Enhancing α-secretase Processing for Alzheimer's Disease-A View on SFRP1 |
Q89965577 | Modulation of Immune Responses by Platelet-Derived ADAM10 |
Q89187503 | Novel therapies for combating chronic neuropathological sequelae of TBI |
Q60046944 | Rusty Microglia: Trainers of Innate Immunity in Alzheimer's Disease |
Q89578231 | Substrate-Specific Activation of α-Secretase by 7-Deoxy-Trans-Dihydronarciclasine Increases Non-Amyloidogenic Processing of β-Amyloid Protein Precursor |
Search more.